Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Once-daily ZD4054 10 mg in non-metastatic hormone-resistant prostate cancer
2007-003224-38Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Nov 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in castration-resistant prostate cancer (CRPC) comparing ZD4054 10 mg once daily with Placebo once daily (2 arms). Primary endpoint: Overall survival. Started Nov 2007; status: completed.
02
Drugs
zibotentan
03
Conditions
castration-resistant prostate cancer (CRPC)
Beyond the preview
Go deeper on 2007-003224-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-003224-38.